06938 瑞博生物－Ｂ
RIBOLIFE-B
RIBOLIFE-B
| Listing Date | 2026/01/09 Listed Today |
| Listing Price | 57.970 |
Quote
Subscription Result
- Subscription Rate101.06x
- Guarantee One Lot Size100 lot
- One Lot Success Rate1.71%
|
|
|
|
|
|
|
|
|
|
IPO Detail
COMPANY PROFILE
Suzhou Ribo Life Science Co. was founded in 2007, it is a biopharmaceutical company engaged in oligonucleotide research and development, with a focus on siRNA therapeutics.
--
The Group has one Core Product, RBD4059 (FXI-targeting siRNA), targeting thrombotic diseases, among a pipeline of seven in-house discovered drug assets in clinical trials for seven indications across cardiovascular, metabolic, renal and liver diseases, including four in phase 2 clinical trials.
--
Leveraging the Group’s RiboGalSTAR platform equipped with proprietary and clinically validated GalNAc delivery technology, it has consistently advanced siRNA programs in-house from discovery through clinical development.
--
Besides the Group’s Core Product RBD4059, it is advancing other clinical-stage products, including RBD5044 and RBD1016. Beyond the Group’s clinical pipeline, it maintain over 20 preclinical programs that it aim to advance into clinical development. The Group’s revenue was primarily from its licensing and collaboration arrangements.
BASIC INFORMATION
| Market | Hong Kong (Main Board) |
| Business Nature | Health Care |
| Major Business Area | China |
| Board Lot | 200 |
GLOBAL OFFERING
| No. of Offer Shares | 31.61M H shares |
| No. of International Offer Shares | 28.86M H shares |
| No. of HK Offer Shares | 2.75M H shares |
| Offer Price | $57.97 |
| Stock Code | 6938 |
| Sponsor(s) | China International Capital Corporation Hong Kong Securities Limited, Citigroup Global Markets Asia Limited |
| Underwriter(s) | China International Capital Corporation Hong Kong Securities Limited, Citigroup Global Markets Asia Limited, ICBC International Securities Limited, BOCI Asia Limited, Macquarie Capital Limited, ABCI Securities Company Limited, SDIC Securities (Hong Kong) Limited, Futu Securities International (Hong Kong) Limited |
TIME TABLE
| Application Period | Dec 31 (Wed) - noon, Jan 06 (Tue) |
| Price Determination Date | Jan 06 (Tue) |
| Result Announcement Date | On or before Jan 08 (Thu) |
| Result Announcement Date | On or before Jan 08 (Thu) |
| Result Announcement Date | On or before Jan 09 (Fri) |
| Dealings in Shares commence on | Jan 09, 2026. (Fri) |
Reallocation of Shares Offered
Sales Statistics (HKD)
| Offer Price | $57.97 |
| Capitalization | 9.37B |
| NAV / share ($) | $8.5 (Unaudited pro forma adj NAV / share) |
Use Of Proceeds
| Assuming the offer price being at HKD 57.97, the net proceeds raised would be HKD 1.47B, of which |
| 37.4% : Research and development of Core Product RBD4059 |
| 19.6% : Research and development of RBD5044 |
| 15.9% : Research and development of RBD1016 |
| 10.1% : Fund the research and development of our IND-enabling pipeline assets |
| 8.9% : Advance preclinical assets which have not yet entered the IND-enabling stage and enhance technology platforms |
| 8.1% : Working capital |
IPO NEWS
| 09/01/2026 09:20 |
| {New Stock}RIBOLIFE-B(06938) opens up 29.38% at HK$75 |
| 08/01/2026 18:35 |
| {New Stock}RIBOLIFE-B(06938) ends up 29.03% on grey market |
| 08/01/2026 16:20 |
| {New Stock}RIBOLIFE-B up 28.52% at HK$74.5 on grey market |
Related Document
| Prospectus |  Chinese Version | English Version |
| Remark： | The above information is referenced from the prospectus. |
| All data is calculated from the non- exercise rights(if applicable). |
Name︰
--
--
--
Subscription --
Result Announcement --
Listing --Offer Price︰--
| Currency | : |
| Listing Price | : |
| Board Lot | : |
| Admission Fee* |
: |
| Subscribing Lot | : |
| Subscribing Fee | : |
| Subscribing Amount | : |
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).